New Century Financial Group LLC Has $788,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

New Century Financial Group LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 16.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,016 shares of the medical research company’s stock after selling 584 shares during the quarter. New Century Financial Group LLC’s holdings in Amgen were worth $788,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Insigneo Advisory Services LLC boosted its position in shares of Amgen by 31.7% in the second quarter. Insigneo Advisory Services LLC now owns 3,864 shares of the medical research company’s stock valued at $1,257,000 after acquiring an additional 930 shares during the period. APG Asset Management US Inc. raised its stake in Amgen by 2.2% in the 2nd quarter. APG Asset Management US Inc. now owns 158,539 shares of the medical research company’s stock worth $49,307,000 after purchasing an additional 3,450 shares in the last quarter. APG Asset Management N.V. boosted its holdings in Amgen by 11.8% in the 2nd quarter. APG Asset Management N.V. now owns 629,733 shares of the medical research company’s stock valued at $183,588,000 after purchasing an additional 66,416 shares during the period. Drucker Wealth 3.0 LLC acquired a new position in shares of Amgen during the 2nd quarter worth approximately $3,167,000. Finally, Delta Investment Management LLC increased its holdings in shares of Amgen by 3.3% during the second quarter. Delta Investment Management LLC now owns 1,903 shares of the medical research company’s stock worth $595,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $277.88 on Friday. The stock has a market capitalization of $149.37 billion, a price-to-earnings ratio of 35.58, a PEG ratio of 2.79 and a beta of 0.56. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The stock’s 50 day moving average price is $271.91 and its two-hundred day moving average price is $306.43.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. Amgen’s revenue was up 23.2% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.43%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 115.24%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AMGN shares. TD Cowen boosted their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. UBS Group reduced their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Royal Bank of Canada dropped their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Finally, Leerink Partners dropped their target price on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.